5NRA Stock Chart & Stats
€36.00
-€0.80(-2.38%)
At close: 4:00 PM EDT
€36.00
-€0.80(-2.38%)
Day’s Range― - ―
52-Week Range€9.85 - €47.40
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€1.51B
Enterprise Value€1.17K
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume7
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.74Price Target Upside54.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€21.12M
Bulls Say, Bears Say
Bulls Say
Nanomedicine PlatformNanobiotix’s physics-driven nanomedicine approach targets a meaningful oncology need by intensifying radiotherapy effects at the tumor site. A platform that may extend across treatment modalities could support multiple development opportunities and provide differentiation as clinical evidence accumulates.
Strategic Partnership ModelThe Janssen relationship gives Nanobiotix access to a major strategic partner and creates several potential sources of non-product funding. Upfront payments, development milestones, and future royalties could improve commercialization reach and reduce reliance on building a sales infrastructure alone.
Pipeline And Intellectual PropertyA broad patent portfolio can help protect Nanobiotix’s technology while its late-stage pipeline advances toward potential commercialization. Together, intellectual-property protection and clinical maturity may strengthen partnering leverage and preserve longer-term value from successful development.
Bears Say
Persistent UnprofitabilityNanobiotix has not yet demonstrated sustainable profitability despite the 2025 revenue rebound. Continuing operating and net losses indicate that development activity is consuming more value than current revenue generates, leaving future earnings dependent on clinical progress and successful commercialization.
Persistent Cash BurnConsistently negative operating and free cash flow means Nanobiotix cannot currently fund operations from internally generated cash. Ongoing burn increases dependence on external funding, which may constrain development plans or dilute existing holders if additional capital is required.
Weak Balance SheetNegative equity combined with debt exceeding reported assets signals materially weakened capitalization and limited financial flexibility. Higher leverage can make it harder to absorb setbacks, fund clinical programs, or negotiate from strength when additional financing is needed.
5NRA FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was €9.85 and its highest was €47.40 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is €1.51B.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Sep 30, 2026 which is in 9 days.
How were Nanobiotix’s earnings last quarter?
Nanobiotix released its earnings results on Mar 31, 2026. The company reported -€0.393 earnings per share for the quarter, beating the consensus estimate of -€0.439 by €0.047.
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 50,619,583 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Nanobiotix reported an EPS of -€0.393 in its last earnings report, beating expectations of -€0.439. Following the earnings report the stock price went down -5.699%.
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in DE:5NRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Nanobiotix
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
5NRA Stock 12 Month Forecast
Average Price Target
€55.74
▲(54.82% Upside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―